Pharmaceuticals, Biotechnology and Life Sciences
Active Biotech, a Sweden- based biotechnology company, has entered into an exclusive license agreement with Oncode Institute in the Netherlands, for the global rights to patents relating to the use of tasquinimod and other inhibitors of S100 for use in treatment of myelofibrosis (MF).
Teva Pharmaceutical Industries and Active Biotech have reported that the CONCERTO trial in patients with relapsing-remitting multiple sclerosis (RRMS) did not meet its primary endpoint.
U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Active Biotech for its investigational novel agent tasquinimod, for the treatment of multiple myeloma.
Active Biotech has reported net loss of € 1,6 million for Q4, which is decrease of loss comparing to the same period 2015 when the net loss was € 4,3 million.
The European Patent Office has decided to grant Active Biotech’s patent application covering tasquinimod for use in the treatment of…
Active Biotech has announced on Tuesday that following the end of the subscription period, the results of Active Biotech’s rights issue…